What are Multi-kinase inhibitor drugs?

Multi-kinase inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting BRAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, c-KIT). 3 are currently marketed, with 5 more in clinical development.

What are the marketed Multi-kinase inhibitor drugs?

Marketed Multi-kinase inhibitor drugs include Sorafenib Ramp-Up Regimen, Sorafenib Standard Dosing Regimen, Sorafenib (SORA).

Multi-kinase inhibitor

3 marketed 4 in Phase 3 1 in Phase 2

This page covers all Multi-kinase inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting BRAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, c-KIT, RAF, VEGFR-2, VEGFR-3, PDGFR-β, RAF, VEGFR, PDGFR.

Targets

BRAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, c-KIT · RAF, VEGFR-2, VEGFR-3, PDGFR-β · RAF, VEGFR, PDGFR · RAF kinase, VEGFR, PDGFR · VEGFR, PDGFR, FGFR, and other kinases

Marketed (3)

Sorafenib Ramp-Up Regimen · University of Florida · Oncology
Sorafenib is a multi-kinase inhibitor that blocks RAF, VEGFR, and PDGFR signaling to inhibit tumor cell proliferation and angiogenesis.
Sorafenib Standard Dosing Regimen · University of Florida · Oncology
Sorafenib is a multi-kinase inhibitor that blocks several receptor tyrosine kinases involved in tumor cell proliferation and angiogenesis.
Sorafenib (SORA) · Nanfang Hospital, Southern Medical University · Oncology
Sorafenib is a multi-kinase inhibitor that blocks RAF, VEGFR, and PDGFR signaling to inhibit tumor cell proliferation and angiogenesis.

Phase 3 pipeline (4)

Sorafenib+Pazopanib · Technical University of Munich · Oncology
Sorafenib and Pazopanib are multi-kinase inhibitors that target various pathways involved in tumor growth and angiogenesis.
Sorafenib Tosylate Tablets · Beijing Shenogen Biomedical Co., Ltd · Oncology
Sorafenib Tosylate Tablets inhibit multiple intracellular and cell surface kinases, which are involved in tumor growth and angiogenesis.
SKLB1028 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Oncology
SKLB1028 is a tyrosine kinase inhibitor that targets multiple kinases involved in cancer cell proliferation and survival.
Oral Sorafenib · Sun Yat-sen University · Oncology
Sorafenib is a multi-kinase inhibitor that blocks RAF, VEGFR, and PDGFR signaling to inhibit tumor cell proliferation and angiogenesis.

Phase 2 pipeline (1)

Lenvatinib and Sorafenib · Stephen Chan Lam · Oncology
Multi-kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), fibroblast growth factor receptors (FGFR), and other kinases.